Condition: Ampullary Adenocarcinoma · Sponsor: Fondazione Poliambulanza Istituto Ospedaliero
Ampullary adenocarcinoma (AAC) is a rare gastrointestinal cancer with varying survival rates, particularly the aggressive pancreatobiliary (PB) subtype. Adjuvant therapy benefits only PB and mixed subtype patients, while prospective studies are required for validation. A study proposes tailored adjuvant treatments (CAPOX for intestinal subtype, FOLFIRINOX for PB and mixed subtypes) based on histopathology to enhance survival, also exploring molecular sub-studies for deeper insights.
This description comes directly from the study's public registry record.
Moh'd Abu Hilal, MD, PhD · +393756326711 · abuhilal9@gmail.com
Bas Uijterwijk · 0640380827 · basuijterwijk@live.nl
Always discuss trial participation with your own doctor first.
| Fondazione Poliambulanza | Brescia, BS, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06068023